1-乙基哌啶-4-羧酸甲酯 | 99065-42-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-乙基哌啶-4-羧酸甲酯
• 英文名称: 1-ethyl-piperidine-4-carboxylic acid methyl ester
• 英文别名: 1-Aethyl-piperidin-4-carbonsaeure-methylester；methyl-1-ethyl-4-piperidine-carboxylate；Methyl 1-ethylpiperidine-4-carboxylate
• CAS: 99065-42-6
• 化学式: C₉H₁₇NO₂
• mdl: MFCD09839681
• 分子量: 171.239
• InChiKey: AYLUKTKPNDSZBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-乙基哌啶-4-羧酸甲酯 在 甲醇 、 lithium hydroxide 作用下， 反应 1.0h， 以700 mg的产率得到1-乙基哌啶-4-羧酸盐酸盐
  参考文献：
  名称：

  QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF

  摘要：

  本发明涉及一种新型化合物，具有抗癌治疗活性。本发明还涉及该化合物的制备方法和含有该化合物的药物组合物。

  公开号：

  EP3967695A1
• 作为产物：
  描述：

  1-乙基-4-甲氧基羰基碘吡啶 在 乙醇 、 铂 作用下， 生成 1-乙基哌啶-4-羧酸甲酯
  参考文献：
  名称：

  Parasympathetic Blocking Agents. III. N-Alkylpiperidinecarboxylic Esters¹

  摘要：

  DOI：

  10.1021/ja01512a050

文献信息

• JAK INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2108642A1

  公开（公告）日：2009-10-14

  A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.

  一种JAK抑制剂，其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同，每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物，或类似物;而 R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
• FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF
  申请人：SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

  公开号：US20160214994A1

  公开（公告）日：2016-07-28

  Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.

  揭示了一种融合嘧啶化合物，其中间体，制备方法以及其组成和应用。本发明提供了一种如式I所示的融合嘧啶化合物，该化合物的药用可接受盐，水合物，溶剂合物，以及光学异构体或前药。本发明还提供了应用式I所示的融合嘧啶化合物，药用可接受盐，水合物，溶剂合物，以及该化合物的光学异构体或前药在制备用于治疗和/或预防激酶相关疾病的药物中。本发明的融合嘧啶化合物I是一种高效的PI3激酶抑制剂，可用于制备用于预防和/或治疗细胞增殖性疾病，如癌症，感染，炎症和自身免疫疾病的药物。
• SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS
  申请人：BIGNAN Gilles

  公开号：US20110150864A1

  公开（公告）日：2011-06-23

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  该发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎、动脉粥样硬化、关节炎（如类风湿性关节炎、感染性关节炎、儿童关节炎、银屑病性关节炎、反应性关节炎）、与骨相关的疾病（包括与骨形成有关的疾病）、乳腺癌（包括对抗雌激素治疗无效的癌症）、心血管疾病、软骨相关疾病（如软骨损伤/丧失、软骨退化以及与软骨形成有关的疾病）、软骨发育不良、软骨肉瘤、慢性腰部损伤、慢性支气管炎、慢性炎症性气道疾病、慢性阻塞性肺疾病、糖尿病、能量稳态紊乱、痛风、假性痛风、脂质紊乱、代谢综合征、多发性骨髓瘤、肥胖、骨关节炎、遗传性骨发育不全、骨转移性溶骨性转移、软骨软化症、骨质疏松症、帕金森病、牙周病、多肌痛风、Reiter综合征、重复性应激损伤、高血糖、血糖水平升高和胰岛素抵抗等疾病的条件。
• [EN] SUBSTITUTED PYRIMIDINES AND METHODS OF USE<br/>[FR] PYRIMIDINES SUBSTITUÉES ET MÉTHODES D'UTILISATION
  申请人：THERAVANCE BIOPHARMA R&D IP LLC

  公开号：WO2021203131A1

  公开（公告）日：2021-10-07

  The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

  本公开提供了抑制活性素受体样激酶5（ALK5）的抑制剂。还公开了调节ALK5活性的方法以及治疗由ALK5介导的疾病的方法。
• Aminoketones of substituted dibenzo- and pyridobenzo-azepinones and pharmaceutical compositions
  申请人：ISTITUTO DE ANGELI S.p.A.

  公开号：EP0326526A1

  公开（公告）日：1989-08-02

  New pharmacologically active aminoketones of substituted dibenzo-and pyri­dobenzo-azepinones as selective antimuscarinic agents, useful in the treatment of diseases of the gastrointestinal tract of general formula (I) wherein R represents a C₁₋₄ alkyl, A and B represent independently nitrogen or carbon with the proviso that A and B cannot be nitrogen at the same time X represents a substituent at a carbon atom of the fused rings selec­ted from hydrogen, halogen, methyl, and acid addition salts thereof. The process for the preparation of the compounds of general formula (I) as well as pharmaceutical compositions containing them are also described.

  新的药理活性氨基酮类化合物，属于取代的二苯并及吡啶并-二苯并-氮烯酮类化合物，作为选择性抗胆碱药物，在治疗胃肠道疾病方面有用，其通式为（I）其中R代表C₁₋₄烷基，A和B分别独立地代表氮或碳，但A和B不能同时为氮，X代表融合环的碳原子上的取代基，可以是氢、卤素、甲基，以及其酸加成盐。本文还描述了通式（I）化合物的制备方法以及含有它们的药物组合物。